Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2020-07-02 Regulatory Filings
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 2, 2020, by Anixa Biosciences, Inc. It announces a strategic realignment of the company's business focus and suspension of a product development. The document includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The content is an announcement of a significant corporate event rather than a full report or detailed financial disclosure. Form 8-K filings typically fall under Regulatory Filings (RNS) as they are general regulatory announcements that do not fit other specific categories. The document length is 3429 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-07-02 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed under Schedule 14A pursuant to the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on such as election of directors, advisory approval of executive compensation, ratification of auditors, and amendment to the certificate of incorporation. The document is clearly a solicitation of proxies and contains detailed proxy materials for the meeting. It is not an announcement of voting results, nor is it a report of financial results or management discussion. The document is not a full annual report or earnings release but is specifically a proxy statement related to governance and shareholder voting matters. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement or notice.
2020-06-22 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-17 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-16 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-12 English
FORM 10-Q
Interim / Quarterly Report Q2 2020
2020-06-09 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.